# A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

> **NCT07013474** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 300 (estimated)

## Conditions studied

- COVID-19 Infection

## Interventions

- **DRUG:** ibuzatrelvir
- **DRUG:** remdesivir
- **DRUG:** placebo for ibuzatrelvir
- **DRUG:** placebo for remdesivir

## Key facts

- **NCT ID:** NCT07013474
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2026-12-06
- **Final completion:** 2027-05-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07013474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07013474, "A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT07013474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*